全文获取类型
| 收费全文 | 15877篇 |
| 免费 | 985篇 |
| 国内免费 | 57篇 |
专业分类
| 耳鼻咽喉 | 219篇 |
| 儿科学 | 520篇 |
| 妇产科学 | 388篇 |
| 基础医学 | 2181篇 |
| 口腔科学 | 299篇 |
| 临床医学 | 1362篇 |
| 内科学 | 3796篇 |
| 皮肤病学 | 545篇 |
| 神经病学 | 1320篇 |
| 特种医学 | 447篇 |
| 外科学 | 1992篇 |
| 综合类 | 90篇 |
| 一般理论 | 5篇 |
| 预防医学 | 1524篇 |
| 眼科学 | 234篇 |
| 药学 | 916篇 |
| 中国医学 | 77篇 |
| 肿瘤学 | 1004篇 |
出版年
| 2023年 | 128篇 |
| 2022年 | 231篇 |
| 2021年 | 600篇 |
| 2020年 | 285篇 |
| 2019年 | 498篇 |
| 2018年 | 598篇 |
| 2017年 | 360篇 |
| 2016年 | 322篇 |
| 2015年 | 434篇 |
| 2014年 | 607篇 |
| 2013年 | 788篇 |
| 2012年 | 991篇 |
| 2011年 | 1018篇 |
| 2010年 | 623篇 |
| 2009年 | 600篇 |
| 2008年 | 836篇 |
| 2007年 | 831篇 |
| 2006年 | 809篇 |
| 2005年 | 821篇 |
| 2004年 | 796篇 |
| 2003年 | 747篇 |
| 2002年 | 695篇 |
| 2001年 | 374篇 |
| 2000年 | 413篇 |
| 1999年 | 340篇 |
| 1998年 | 117篇 |
| 1997年 | 82篇 |
| 1996年 | 106篇 |
| 1995年 | 84篇 |
| 1994年 | 68篇 |
| 1993年 | 64篇 |
| 1992年 | 181篇 |
| 1991年 | 152篇 |
| 1990年 | 151篇 |
| 1989年 | 135篇 |
| 1988年 | 136篇 |
| 1987年 | 115篇 |
| 1986年 | 100篇 |
| 1985年 | 87篇 |
| 1984年 | 70篇 |
| 1983年 | 45篇 |
| 1982年 | 26篇 |
| 1979年 | 52篇 |
| 1978年 | 24篇 |
| 1977年 | 24篇 |
| 1976年 | 32篇 |
| 1975年 | 37篇 |
| 1974年 | 44篇 |
| 1973年 | 24篇 |
| 1972年 | 28篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
1.
2.
María del Carmen Azorín Samper Marta Hernandorena Gonzlez Alberto Ibez Arias Sandra Díaz Sierra Marta Bertolo Domínguez Flix Checa Ayet 《The breast journal》2020,26(2):252-254
Breast pseudoaneurysms after a core needle biopsy are a rare complication with a low incidence. However, it is important to be aware of the possibility of complications that require treatment. 相似文献
3.
A case of Rubinstein‐Taybi syndrome associated with growth hormone deficiency in childhood 
下载免费PDF全文
下载免费PDF全文 4.
5.
6.
7.
8.
9.
Julia Thornton Snider Jesse Sussell Mahlet Gizaw Tebeka Alicia Gonzalez Joshua T. Cohen Peter Neumann 《Value in health》2019,22(3):332-339
Background
Payers frequently rely on budget impact model (BIM) results to help determine drug coverage policy and its effect on their bottom line. It is unclear whether BIMs typically overestimate or underestimate real-world budget impact.Objective
We examined how different modeling assumptions influenced the results of 6 BIMs from the Institute for Clinical and Economic Review (ICER).Study Design
Retrospective analysis of pharmaceutical sales data.Methods
From ICER reports issued before 2016, we collected estimates of 3 BIM outputs: aggregate therapy cost (ie, cost to treat the patient population with a particular therapy), therapy uptake, and price. We compared these against real-world estimates that we generated using drug sales data. We considered 2 classes of BIM estimates: those forecasting future uptake of new agents, which assumed “unmanaged uptake,” and those describing the contemporaneous market state (ie, estimates of current, managed uptake and budget impact for compounds already on the market).Results
Differences between ICER's estimates and our own were largest for forecasted studies. Here, ICER's uptake estimates exceeded real-world estimates by factors ranging from 7.4 (sacubitril/valsartan) to 54 (hepatitis C treatments). The “unmanaged uptake” assumption (removed from ICER's approach in 2017) yields large deviations between BIM estimates and real-world consumption. Nevertheless, in some cases, ICER's BIMs that relied on current market estimates also deviated substantially from real-world sales data.Conclusions
This study highlights challenges with forecasting budget impact. In particular, assumptions about uptake and data source selection can greatly influence the accuracy of results. 相似文献10.